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Abstract
Klebsiella (K.) pneumoniae is a common cause of pneumonia-derived sepsis. Myeloid related protein 8 (MRP8, S100A8) and
MRP14 (S100A9) are the most abundant cytoplasmic proteins in neutrophils. They can form MRP8/14 heterodimers that are
released upon cell stress stimuli. MRP8/14 reportedly exerts antimicrobial activity, but in acute fulminant sepsis models
MRP8/14 has been found to contribute to organ damage and death. We here determined the role of MRP8/14 in K.
pneumoniae sepsis originating from the lungs, using an established model characterized by gradual growth of bacteria with
subsequent dissemination. Infection resulted in gradually increasing MRP8/14 levels in lungs and plasma. Mrp14 deficient
(mrp142/2) mice, unable to form MRP8/14 heterodimers, showed enhanced bacterial dissemination accompanied by
increased organ damage and a reduced survival. Mrp142/2 macrophages were reduced in their capacity to phagocytose
Klebsiella. In addition, recombinant MRP8/14 heterodimers, but not MRP8 or MRP14 alone, prevented growth of Klebsiella in
vitro through chelation of divalent cations. Neutrophil extracellular traps (NETs) prepared from wildtype but not from
mrp142/2 neutrophils inhibited Klebsiella growth; in accordance, the capacity of human NETs to kill Klebsiella was strongly
impaired by an anti-MRP14 antibody or the addition of zinc. These results identify MRP8/14 as key player in protective
innate immunity during Klebsiella pneumonia.
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Introduction
Klebsiella (K.) pneumoniae is a frequent causative pathogen in
pneumonia [1,2] and the second most common cause of gram-
negative sepsis [3,4]. Klebsiella infection presents a significant
burden on healthcare and is associated with high morbidity and
mortality rates. Effective treatment of this microorganism is even
more challenging due to the emergence of microbial resistance to
(last-resort) antibiotics [5,6]. It is therefore of great importance to
expand our understanding on host defense mechanisms that
influence the outcome of Klebsiella pneumonia. Such knowledge
may eventually help in the development of new therapies.
Invasive infection and accompanying inflammatory mecha-
nisms can cause tissue damage that is associated with release of
endogenous ‘‘alarm’’ proteins. These proteins, also known as
Damage Associated Molecular Patterns (DAMPs), are recognized
by pattern recognition receptors and perpetuate inflammatory
responses [7,8]. Among these DAMPs, the S100 proteins MRP8
(myeloid-related protein, S100A8) and MRP14 (S100A9) have
gained increasing interest [9,10]. They are mainly and constitu-
tively expressed in neutrophils where they comprise 45 percent of
total cytoplasmic protein [11]. MRP8 and MRP14 are able to
dimerize with a clear preference for the most stable and
biologically relevant MRP8/14 heterodimer (or calprotectin),
which can be actively released into the extracellular space [12–
15]. MRP8/14 induces a variety of host responses and the extent
of expression correlates with clinical [9,10] and experimental [16]
disease activity. Previous investigations have pointed to a complex
role of MRP8/14 in severe infection, which may either be
protective or harmful to the host. MRP8/14 can enhance
inflammation via activation of Toll-like receptor (TLR)4, by
amplifying tumor necrosis factor (TNF)-a release in response to
lipopolysaccharide (LPS), the immunostimulatory component of
the gram-negative bacterial cell wall. In the setting of fulminant
systemic inflammation such as induced by high dose LPS or
Escherichia (E.) coli administration, endogenous MRP8/14 contrib-
utes to lethality [15]. On the opposite site, MRP8/14 may be
important for innate defense against microorganisms by virtue of
its involvement in leukocyte migration [17–20] and its direct
antimicrobial effects [21–23]. In addition, recent studies revealed
PLOS Pathogens | www.plospathogens.org 1 October 2012 | Volume 8 | Issue 10 | e1002987
that MRP8/14 is a major component of neutrophil extracellular
traps (NETs) [24], DNA-networks released by neutrophils that
trap microorganisms and facilitate interaction with antimicrobial
proteins and thereby bacterial killing [25,26]. Although at present
the importance for NET associated MRP8/14 for bacterial killing
is unknown, the presence of MRP8/14 was found to be crucial for
the clearance of fungi by NETs in vitro [24,27].
In the present study, we aimed to characterize the role of
MRP8/14 during pneumonia-originating sepsis caused by K.
pneumoniae. For this we used mrp14 deficient (mrp142/2) mice,
which due to instability of MRP8 in the absence of its binding
partner MRP14 are considered deficient for MRP8/14 at protein
level [28–30]. We here show that MRP8/14 deficiency results in
enhanced bacterial dissemination, increased distant organ damage
and a reduced survival during Klebsiella pneumonia. Using in vitro
models, we show that mrp142/2 macrophages have a reduced
capacity to phagocytose this bacterium. We further demonstrate
that MRP8/14 directly reduces the growth of Klebsiella and in
addition is essential in NET-mediated growth inhibition of this
pathogen. These results identify MRP8/14 as an important
protective mediator in the innate immune response to bacterial
pneumonia caused by a clinically relevant pathogen.
Results
MRP8/14 levels increase during pneumonia
To gain a first insight into the potential role of MRP8/14 in gram-
negative pneumonia, we intranasally infected Wt mice with K.
pneumoniae (104 cfu) and measured local and systemic MRP8/14
concentrations 6, 24 and 48 hours thereafter. MRP8/14 levels
became detectable in BAL fluid at 24 hours after infection; high levels
were found at 48 hours (median 745 ng/ml; Fig. 1A). In whole lung
homogenates, MRP8/14 was detectable at low levels in uninfected
mice and concentrations did not increase during the first 6 hours after
infection; high MRP8/14 levels were detected at later time points
(median 200 mg/ml at 24 hours; Fig. 1B). Plasma MRP8/14 levels
also increased during the course of the infection, reaching peak
concentrations at 48 hours (median 440 ng/ml; Fig. 1C).
To obtain insight into the cellular source of MRP8/14, we
stained lung tissue slides obtained from naı¨ve and infected Wt mice
for MRP8 and MRP14. Bronchial epithelium of naı¨ve lungs
showed a faint staining for MRP8 (but not MRP14) that did not
intensify during Klebsiella pneumonia. A small number of MRP8
and MRP14 positive cells, mainly residing macrophages, were
already present. During the course of the disease, expression of
both MRP8 and MRP14 increased strongly, primarily as a
consequence of infiltrating neutrophils (Fig. 1D–I).
Mrp14 deficiency impairs host defense during
pneumonia
To investigate the functional role of MRP8/14 in host defense
during gram-negative pneumonia, we infected mrp142/2 and Wt
mice with 104 viable K. pneumoniae and harvested lungs, blood,
spleen and livers at predefined time points for quantitative
cultures, seeking to collect data representative for local defense,
at the primary site of infection, and subsequent dissemination.
Initially, mrp142/2 mice showed slightly lower bacterial loads in
lungs compared to Wt mice (Fig. 2A; p,0.001). At later time
points, mrp142/2 mice tended to have higher bacterial burdens in
their lungs. Remarkably, at late stage infection (after 48 hours,
shortly before the first deaths occurred) mrp142/2 mice displayed
increased bacterial loads in blood, liver (both p,0.01) and spleen
(p,0.05), suggesting that MRP14 deficiency is associated with
enhanced dissemination of the infection (Fig. 2B–D). To investi-
gate the impact of the reduced antibacterial defense in mrp142/2
mice on survival, we performed an observational study instilling
the same infectious dose (104 cfu) as used in the experiments
determining bacterial growth and spreading (Fig. 2E). This
inoculum rapidly led to death shortly after 48 hours in all mice;
notably, mrp142/2 mice tended to die earlier in this lethal model
(p = 0.10 versus Wt mice). Arguing that the infectious challenge
might have been too high to reveal a detrimental effect of MRP14
deficiency on survival, we repeated this observational study with a
10-fold lower inoculum (103 cfu; Fig. 2F). This infectious dose
resulted in a 56% lethality in Wt mice 10 days after inoculation;
mrp142/2 mice displayed a higher mortality rate and eventually
94% of mrp142/2 mice died (p = 0.0008 versus Wt mice). These
data establish the important protective role of MRP8/14 in K.
pneumoniae pneumonia as reflected by an increased dissemination of
bacteria and a reduced survival.
The fact that MRP14 deficiency in particular influenced
bacterial loads in distant organs led us to hypothesize that
mrp142/2 mice would also show enhanced bacterial growth after
direct intravenous injection of K. pneumoniae. Indeed, 48 hours after
intravenous infection with 26103 Klebsiella cfu, mrp142/2 mice
demonstrated higher bacterial burdens in spleen, liver and lungs
(all p,0.01; Fig. S1). These data suggest that MRP8/14
importantly contributes to systemic protection against K. pneumoniae
infection.
MRP14 deficiency does not influence neutrophil
recruitment into the lungs
Bacterial pneumonia is associated with neutrophil migration to
the lung parenchyma, which is considered to be an essential
component of a protective innate immune response [31,32].
Previous studies indeed have documented that neutrophils play an
important role in innate defense early after Klebsiella airway
infection [33,34]. MRP8/14 has been implicated as an important
mediator of neutrophil recruitment in various inflammatory
conditions [17–19,35], including pneumonia [20]. Therefore, we
determined the extent of neutrophil influx in mrp142/2 and Wt
Author Summary
Neutrophils are phagocytes that are well known for their
capacity to engulf and kill microbial pathogens. It has
become increasingly clear that neutrophils also kill or
inhibit growth extracellularly by releasing neutrophil
extracellular traps (NETs), chromatin fibers decorated with
neutrophil derived proteins. MRP8/14 has been identified
as one of the major antimicrobial proteins herein. Previous
investigations have shown that endogenously released
MRP8/14 is also sensed by the host as a danger signal and
able to potentiate the harmful systemic inflammatory
response syndrome. Indeed, in the setting of fulminant
systemic inflammation, such as induced by endotoxin or
Escherichia coli administration, MRP8/14 contributed to
organ injury and mortality. The clinical scenario of sepsis
however, involves an initial infection at the primary site
followed by bacterial spreading to other organs. In the
present setting of pneumonia-derived sepsis using the
common human respiratory and sepsis pathogen Klebsiella
pneumoniae MRP8/14 clearly served a beneficial role in
antimicrobial defense. We here provide a likely mechanism
by showing that MRP8/14 plays a role in phagocytosis and
that its presence is critical in both murine and human NETs
to inhibit bacterial growth.
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mice at 6, 24 and 48 hours after intranasal challenge with K.
pneumoniae by assessing the number of Ly-6G positive cells in lung
tissue sections and by measuring MPO concentrations in whole
lung homogenates (Fig. 3). Neither the number of Ly-6G positive
cells, nor whole lung MPO concentrations differed between
mrp142/2 and Wt mice at any time point; if anything, mrp142/2
mice tended to have more Ly-6G positive cells and higher MPO
levels in their lungs than Wt mice. Hence, these data strongly
argue against a role for MRP8/14 in neutrophil influx into the
lungs during Klebsiella pneumonia.
MRP14 deficiency results in increased lung pathology
This model of K. pneumoniae pneumonia is associated with
profound lung inflammation [36–38]. Although the presence of
MRP8/14 did not affect lung bacterial loads or neutrophil
recruitment at later time points, we wondered whether lung
pathology would be influenced by the (proinflammatory) effects of
MRP8/14 itself during Klebsiella pneumosepsis. We therefore
analyzed HE-stained lung tissue slides obtained from infected Wt
and mrp142/2 mice using the semi-quantitative scoring system
described in the Materials en Methods section (Fig. 4). Already at
6 hours after infection mild interstitial inflammation and pleuritis
were found in all mice; at later stages endothelialitis, bronchitis
and edema became apparent. Interestingly, after 24 and 48 hours,
mrp142/2 mice showed exaggerated lung pathology with en-
hanced interstitial inflammation, bronchitis and larger surfaces of
confluent inflammation infiltrate. The enhanced lung pathology
may be a reflection of the increased disease severity in mrp142/2
mice and suggest that the presence of MRP8/14, though
proinflammatory, is not essential for the induction of lung
inflammation during Klebsiella pneumosepsis.
Impact of MRP14 deficiency on cytokine and chemokine
levels
Extracellular MRP8/14 has been shown to amplify the TNF-a
response upon LPS stimulation and mrp142/2 bone marrow cells
demonstrated a reduced responsiveness to LPS in vitro [15]. In vivo
this correlated with lower plasma TNF-a levels in mrp142/2 mice
challenged with LPS [15]. To study the impact of MRP14
deficiency on cytokine release in gram-negative pneumonia, we
Figure 1. K. pneumoniae pneumonia results in an increase of endogenous MRP8/14 levels and enhanced MRP8 and MRP14
expression in lungs. MRP8/14 levels in BAL fluid (A), whole lung homogenates (B), and plasma (C) were determined in naive mice (n = 4) and 6, 24
and 48 hours after intranasal K. pneumoniae infection (n = 6–8). Data are expressed as box-and-whisker diagrams depicting the smallest observation,
lower quartile, median, upper quartile and largest observation. MRP8 and MRP14 were stained in lungs of naive and infected mice. Shown here are
representative slides of MRP8 (D) and MRP14 (E) staining of naive mice, MRP8 (F) and MRP14 (G) staining 24 hours and MRP8 (H) and MRP14 (I)
staining 48 hours after infection. Scalebar indicates 200 mm.
doi:10.1371/journal.ppat.1002987.g001
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measured the levels of cytokines (TNF-a, IL-1b, IL-6, IL-10) and
chemokines (MIP-2, KC) in lung homogenates and plasma (TNF-
a, IL-1b and IL-6 only) harvested from mrp142/2 and Wt mice
after intranasal infection with Klebsiella. Surprisingly, overall
differences between mouse strains were limited. In whole lung
homogenates, mrp142/2 mice displayed reduced MIP-2 levels
after 6 hours only; at other time points and for other mediators,
levels were similar between groups (Fig. 5A–F). Similarly, plasma
cytokine levels did not differ between Wt and mrp142/2 mice at 6
or 24 hours post infection; after 48 hours however the plasma
levels of IL-6 and IL-1b were even higher in mrp142/2 mice
compared to the Wt mice (Fig. 5G–I).
We next determined the role of endogenous MRP8/14 in the
inflammatory response to Klebsiella infection in vitro. To this end,
we measured TNF-a levels after incubating whole blood from Wt,
mrp142/2 and tlr42/2 mice with log-increasing loads of viable,
Figure 2. Mrp142/2 mice show enhanced bacterial dissemination and increased mortality during pneumonia derived sepsis caused
by K. pneumoniae. Bacterial loads in the lung (A), blood (B), spleen (C) and liver (D) of K. pneumoniae in Wt (grey) and mrp142/2 mice (white). Data
are expressed as box-and-whisker diagrams depicting the smallest observation, lower quartile, median, upper quartile and largest observation (8
mice per group at each time point). * p,0.05, ** p,0.01 versus Wt mice at the same time point. Survival of Wt and mrp142/2 mice after intranasal
inoculation of 10.000 (E) or 1.000 cfu (F) (n = 12–16 per group in each experiment).
doi:10.1371/journal.ppat.1002987.g002
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growth-arrested Klebsiella for 6 hours. In consistence with our in
vivo data, whole blood obtained from Wt and mrp142/2 mice
displayed a similar cytokine response. Only upon exposure to the
highest bacterial concentration, mrp142/2 whole blood showed a
modestly reduced cytokine response. Whole blood from tlr42/2
mice showed almost no TNF-a release in response to Klebsiella (Fig.
S2). Together, these data indicate that endogenous MRP8/14 has
no, or little contribution to the TLR4 mediated cytokine response
to K. pneumoniae infection.
Mrp142/2 mice demonstrate enhanced liver damage
This model of gram-negative pneumonia-derived sepsis is
associated with hepatocellular injury during late stage infection
[38]. In our time point experiments, MRP14 deficiency was
associated with enhanced bacterial dissemination to distant
organs, including the liver. We were thus interested to what
extent this enhanced bacterial dissemination influenced hepato-
cellular injury in these animals. Microscopic examination
revealed dramatically enhanced pathology in livers from
mrp142/2 mice after 48 hours, reflected by more advanced liver
necrosis accompanied with thrombi and more (micro)abscesses
compared to Wt mice (Fig. 6A–C). Clinical chemistry findings
confirmed the existence of more extensive hepatocellular injury,
i.e. mrp142/2 mice had higher plasma levels of ALT and AST, in
particular 24 hours after infection (Fig. 6D,E). At this time point,
mrp142/2 mice also showed higher plasma LDH concentrations
(indicative for cellular injury in general) relative to Wt mice
(Fig. 6F).
MRP14 deficiency reduces macrophage phagocytosis of
K. pneumoniae
A recent report has shown that addition of MRP14 is able to
enhance bactericidal effects of human neutrophils by means of
improving bacterial phagocytosis capacity [39]. We wondered
whether this would correspond to impaired K. pneumoniae
phagocytosis in mrp142/2 murine phagocytes. To investigate this
possibility, we harvested whole blood and macrophages from naı¨ve
Wt and mrp142/2 mice and compared neutrophil and macro-
phage ability to internalize CFSE-labelled, viable, growth-arrested
K. pneumoniae by FACS. Although MRP8/14 is abundantly present
in neutrophils, mrp142/2 neutrophils only displayed a modest
reduction in their capacity to phagocytose Klebsiella compared to
Wt neutrophils (Fig. 7A). Mrp142/2 macrophages however, were
significantly reduced in their capacity to internalize Klebsiella
bacteria (Fig. 7B). In addition to increased dissemination, the
reduced capacity of macrophages to phagocytose the bacteria most
probably contributed to the enhanced bacterial outgrowth in
mrp142/2 mice during Klebsiella infection in vivo.
Figure 3. Neutrophil influx in Klebsiella pneumonia is not influenced by MRP14 deficiency. MPO levels in whole lung homogenates (A)
and quantitation of pulmonary Ly-6G positivity 6, 24 and 48 hours after infection (B) in Wt (grey) and mrp142/2 mice (white). Data are expressed as
box-and-whisker diagrams depicting the smallest observation, lower quartile, median, upper quartile and largest observation (8 mice per group at
each time point). There were no statistically significant differences between the groups. Representative neutrophil stainings (brown) of Wt (C) and
mrp142/2 mice (D) 6 hours, Wt (E) and mrp142/2 mice (F) 24 hours and Wt (G) and mrp142/2 mice (H) 48 hours after induction of K. pneumoniae
pneumonia.. Scalebar indicates 200 mm.
doi:10.1371/journal.ppat.1002987.g003
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MRP8/14 inhibits growth of Klebsiella in vitro through
metal chelation
MRP8/14 has been shown to inhibit the growth of several
microorganisms by binding of divalent cations [22,24,27]. To
study whether K. pneumoniae growth is affected by MRPs, we grew
bacteria in medium for up to 24 hours in the presence or absence
of MRP8/14 heterodimer, MRP8 homodimer or MRP14
homodimer (all 50 mg/ml). Addition of MRP8/14 heterodimer
almost abolished growth of K. pneumoniae, while MRP8 and
MRP14 homodimers had no effect (Fig. 8A). The growth
inhibitory effect of MRP8/14 was dose dependent (Fig. 8B). To
check whether MRP8/14 induced growth inhibition was due to a
metal chelating effect, zinc was added to medium treated with
10 mg/ml MRP8/14 prior to incubation with bacteria; in this
experiment (Fig. 8C) growth was restored when zinc was added in
increasing amounts. Thus, MRP8/14 inhibits growth of K.
pneumoniae through chelation of metals.
Growth inhibition of Klebsiella by mouse and human
NETs is MRP8/14 dependent
Earlier studies have demonstrated that Klebsiella pneumoniae induces
NET formation in vivo [40]. Using immunofluorescence technique, we
found similar decondensation of nuclei of neutrophils, strongly
indicating the formation of NETs in lungs of both Wt and mrp142/2
mice (Fig. S3). It has recently been shown that MRP8/14 is
abundantly present in NETs and that its presence is critical for fungal
clearance [24,27]. To test whether MRP8/14 is important in NET-
mediated growth inhibition of K. pneumoniae, we stimulated Wt and
mrp142/2 neutrophils with PMA to form NETs and then incubated
these with viable bacteria. NETs from Wt neutrophils inhibited the
growth of Klebsiella, while mrp142/2 NETs did not (Fig. 9A). To
investigate the antibacterial properties of MRP8/14 in human NETs,
we induced NET formation in neutrophils from healthy donors and
then coincubated these with viable Klebsiella in the presence or absence
of a neutralizing polyclonal anti-MRP14 antibody. In line with results
obtained with other pathogens [24–27], human NETs effectively
inhibited the growth of Klebsiella. This effect was strongly dependent on
MRP8/14: addition of an anti-MRP14 antibody, blocking the
chelating effect of MRP8/14 [27], almost completely restored growth
of K. pneumoniae. These data confirm that NET-mediated growth
inhibition of K. pneumoniae in a human system is MRP8/14 dependent.
This growth inhibition may rely on the chelation of divalent cations,
since addition of zinc in excess led to the same, if not an even stronger
effect on growth of Klebsiella (Fig. 9B). The growth-inhibiting role of
MRP8/14 within NETs also applied to other bacteria that are
sensitive to NETs. Both gram-positve S. aureus and gram-negative
Pseudomonas aeruginosa, showed an increased outgrowth in the presence
of anti-MRP14 compared to control IgG (Fig. S4).
Discussion
Gram-negative sepsis is a major challenge in the care of
critically ill patients. Despite the availability of effective antimi-
Figure 4. Mrp142/2 mice show enhanced lung pathology during K. pneumoniae pneumonia. Representative slides of lung haematoxylin
and eosin (HE) staining of Wt (A) and mrp142/2 mice (B) 6 hours, Wt (C) and mrp142/2 mice (D) 24 hours and Wt (E) and mrp142/2 mice (F) 48 hours
after intranasal K. pneumoniae infection. Scalebar indicates 200 mm. Total pathology score at indicated time points post infection in Wt (grey) and
mrp142/2 mice (white) was determined according to the scoring system described in the Methods section (G). Data are expressed as box-and-whisker
diagrams depicting the smallest observation, lower quartile, median, upper quartile and largest observation (8 mice per group at each time point).
* p,0.05 versus Wt mice at the same time point.
doi:10.1371/journal.ppat.1002987.g004
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crobial therapy and supportive care, mortality rates remain up to
30–50% [3,41]. Severe sepsis is associated with the release of
MRP8/14 [16], which in models of endotoxic shock and
fulminant sepsis contributes to organ injury and mortality
[15,16]. The clinical scenario of sepsis, however, involves an
initially localized infectious source with subsequent spreading of
bacteria to distant body sites. We argued that in this setting, quite
different from its previously described detrimental role in acute
systemic sepsis models, MRP8/14 may be an important compo-
nent of protective innate immunity at least in part because of its
antimicrobial properties [21–23]. Thus, in the present study we
aimed to determine the role of MRP8/14 during gram-negative
sepsis originating from the lungs, using an established clinically
relevant pneumonia model characterized by gradual growth of
bacteria at the primary site of infection followed by dissemination,
tissue injury and death [36–38], allowing to study a potential role
of MRP8/14 in both the initial immune response as well as the
subsequent harmful systemic inflammation phase. In summary, we
found that intranasal K. pneumoniae infection resulted in local and
systemic MRP8/14 release and that MRP14 deficiency led to an
increased mortality, most likely as a consequence of enhanced
bacterial outgrowth and organ damage. The beneficial role of this
heterodimer may result from its involvement in phagocytosis and
its strong growth inhibitory effect, while it hardly influenced the
TLR4 mediated cytokine response to Klebsiella.
Severe human sepsis results in systemic release of MRP8/14
irrespective of the primary source of infection [16]. Patients with
sepsis caused by pneumonia display the highest protein levels [16].
In the present mouse study, systemic MRP8/14 levels gradually
increased during the course of the infection. Our current finding of
high MRP8/14 concentrations at the primary site of infection
from 24 hours onward is in accordance with a previous
investigation from our group reporting high local levels of
MRP8/14 in patients and mice with bacterial peritonitis [16].
Of note, however, systemic MRP8/14 levels in mice with E. coli
peritonitis were at least ten times higher after one day than in mice
with Klebsiella pneumonia studied here, which most likely reflects
the fulminant nature of the septic syndrome induced by
intraperitoneal E. coli administration. In these acute challenge
models, such as is also produced by high dose LPS injection,
Figure 5. Cytokine and chemokine levels in lungs and plasma. Lung cytokine (TNF-a, L-1b, IL-6, IL-10) (A–D), chemokine (KC and MIP-2) (E–F)
and plasma cytokine (TNF-a, L-1b, IL-6 ) levels (G–I), 6, 24 and 48 hours after intranasal K. pneumoniae infection in Wt (grey) and mrp142/2 mice
(white). Data are expressed as box-and-whisker diagrams depicting the smallest observation, lower quartile, median, upper quartile and largest
observation (8 mice per group at each time point). * p,0.05, ** p,0.01 versus Wt mice.
doi:10.1371/journal.ppat.1002987.g005
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MRP8/14 was suggested to act as a danger signal enhancing the
cytokine response of LPS via TLR4, thereby potentiating the
harmful systemic inflammatory response syndrome [15,16].
Indeed, after either E. coli or LPS administration, MRP14
deficiency attenuated systemic inflammation and consequently
improved survival in E. coli induced peritonitis and LPS-induced
shock, starting to occur from 20 and 6 hours respectively [15]. In
contrast, in the more clinically relevant sepsis model used here, a
‘‘cytokine storm’’ such as detected after LPS administration was
not induced and mortality only started to occur after 2 days,
allowing the gradually increasing levels of MRP8/14 to serve its
beneficial role in antimicrobial defense.
Of note, whereas MRP14 deficiency clearly reduced systemic
cytokine release after LPS or E. coli injection [15,16], such an effect
was not seen during Klebsiella pneumonia. In contrast, plasma
concentrations of proinflammatory cytokines were higher in
Figure 6. Mrp142/2 mice show enhanced hepatocellular injury during pneumonia derived sepsis caused by Klebsiella. Representative
slides of liver haematoxylin and eosin HE staining of Wt (A) and mrp142/2 mice (B) 48 hours post infection. Livers from mrp142/2 mice displayed
more advanced liver necrosis (#) accompanied with (micro) abscesses ( ). Arrows indicate fibrin deposits as a sign of thrombosis. Scalebar indicates
0.5 mm. Total pathology score was determined at indicated time points in Wt (grey) and mrp142/2 mice (white) according to the scoring system
described in the Methods section (C). Aspartate aminotransferase (AST) (D), alanine aminotransferase (ALT) (E), and lactate dehydrogenase (LDH) (F)
were measured in plasma. Data are expressed as box-and-whisker diagrams depicting the smallest observation, lower quartile, median, upper quartile
and largest observation (8 mice per group at each time point). *p,0.05, **p,0.01 versus Wt mice at the same time point.
doi:10.1371/journal.ppat.1002987.g006
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mrp142/2 mice during late stage infection, whereas lung cytokine
and chemokine levels were largely similar in mrp142/2 and Wt
mice. The increased plasma levels of IL-1b and IL-6 in mrp142/2
mice likely reflect the increased bacterial loads in blood, providing
a more potent proinflammatory stimulus. In accordance with our
in vivo data, MRP14 deficiency had little or no effect on the TLR4
mediated TNF-a response in a 6 hour incubation of whole blood
with growth-arrested K. pneumoniae. Together, these data suggest
that MRP8/14 minimally contributes to the cytokine response in
the context of a gradually growing bacterial load, i.e. can be
compensated for by other mechanisms. Furthermore, lungs from
mrp142/2 mice showed increased inflammation, most likely as a
consequence of the more severe infection in these animals and
indicating that MRP8/14 is not a critical inducer of lung
inflammation during gram-negative pneumosepsis.
In spite of high lung concentrations of MRP8/14, this
heterodimer did not play a significant role in the control of local
infection considering that pulmonary bacterial loads only slightly
differed between mrp142/2 and Wt mice after 24 and 48 hours.
The lack of MRP8/14 did however result in strongly increased
bacterial burdens in blood, spleen and especially the liver. This led
us to postulate that the apparent antimicrobial effect of MRP8/14
primarily resided in organs distant from the lung. Indeed, mrp142/2
mice administered with K. pneumoniae directly intravenously, thereby
bypassing a potential effect of MRP8/14 in the airways, displayed
strongly increased bacterial growth in multiple body sites, including
the spleen and liver. We found a reduced capacity of mrp142/2
macrophages, but not mrp142/2 neutrophils, to phagocytose
Klebsiella in vitro, which may partially explain enhanced bacterial
outgrowth in these organs. Indeed, resident spleen macrophages
form an important barrier to blood-borne pathogens and facilitate
clearance in systemic infection [42]. The vast majority of bacteria
entering the bloodstream are cleared by the liver [43]. Resident liver
macrophages (Kupffer cells), constitute 80–90 percent of total tissue
macrophages in the body [44] and have been attributed to clear the
bulk of bacteria that are taken up by this organ [43]. A number of
more recent studies, however, show that certain pathogens,
including K. pneumoniae, can be cleared even in animals that lack
Kupffer cells and suggest that immigrating neutrophils crucially
contribute in hepatic clearance of circulating bacteria [45–47].
Hence, the exact contribution of MRP14 mediated phagocytosis by
macrophages in our in vivo model remains to be elucidated in further
detail.
Impaired antibacterial defense in the liver may have led to
enhanced formation of (micro)abscesses. Abscesses, contain high
levels of MRP8/14 and could be essential in the control of K.
pneumoniae infection [22,48]. We therefore hypothesize that liver
abscesses deficient for MRP8/14 promote bacterial outgrowth of
Klebsiella and may be the source for further bacterial dissemination.
As a consequence of uncontrolled liver infection, enhanced
hepatocellular damage occurred as reflected by the increased
plasma levels of liver transaminases and enhanced liver pathology.
Several animal studies have implicated MRP8/14 as a mediator
of neutrophil recruitment. In murine air pouch models, pretreat-
ment with blocking antibodies directed against MRP8 and
MRP14 significantly reduced leukocyte migration in response to
LPS [17] or monosodium urate crystals [18]. Anti-MRP8 and
anti-MRP14 antibodies also attenuated leukocyte influx into the
pulmonary compartment during S. pneumoniae pneumonia [20].
Chemotaxis by MRP8/14 may partly act via upregulation of
adhesion molecule expression and induction of CXC chemokines
[35]. In the present study we did not find evidence for a role for
MRP8/14 in chemotaxis: MPO levels in whole lung homogenates
and the number of Ly-6G positive cells in lung tissue slides were
not affected by the loss of MRP8/14 in spite of reduced levels of
the neutrophil attracting chemokine MIP-2 early after infection.
Similarly, we showed earlier that neutrophil numbers in the
peritoneal cavity during E. coli induced peritonitis did not differ
between mrp142/2 and WT mice [16]. MRPs may also mediate
other neutrophil functions like, degranulation phagocytosis and
respiratory burst [39,49]. We however, found a similar capacity of
mrp142/2 and Wt neutrophils to mount a respiratory burst (data
not shown) and to phagocytose when incubated with Klebsiella
bacteria.
Recently, MRP8/14 was found to inhibit Staphylococcus (S.) aureus
growth through chelation of zinc and manganese [22]. Divalent
ion-chelation also reduced the enzymatic activity of superoxide
dismutase thereby inhibiting bacterial virulence [23]. In accor-
Figure 7. Phagocytosis is impaired in MRP14 deficient macrophages. Growth arrested, CFSE-labelled K. pneumoniae were incubated with
peripheral blood neutrophils (A) or macrophages (B) from Wt (grey) and mrp142/2 mice (white) at 4uC (n = 3–4 per mouse strain) or 37uC (n = 6–8 per
mouse strain) for 20 and 60 minutes respectively after which phagocytosis was quantified (see Materials and Methods). Data are expressed as box-
and-whisker diagrams depicting the smallest observation, lower quartile, median, upper quartile and largest observation (8 mice per group at each
time point). *p,0.05.
doi:10.1371/journal.ppat.1002987.g007
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dance, mrp142/2 mice showed higher bacterial loads after
intravenous S. aureus injection [22]. In contrast, mouse studies
investigating abdominal sepsis or urinary tract infection caused by
E. coli [16,50] or pneumonia caused by S. pneumoniae [20] did not
point to an antimicrobial role for MRP8/14. In the present study
we showed that the growth of K. pneumoniae was dose dependently
inhibited by MRP8/14 while neither MRP8 nor MRP14
homodimers affected growth in any way. The antimicrobial effect
of MRP8/14 toward Klebsiella could be overcome by addition of
zinc implicating chelation of divalent cations by MRP8/14 as a
key process herein. During infection, neutrophils can kill
pathogens through different mechanisms, including by the release
of NETs composed of chromatin decorated with neutrophil
derived proteins [24–26]. We here observed the presence of
decondensated nuclei of neutrophils in the lungs strongly
indicating the formation of NETs. Histones have been implicated
as the predominant antibacterial component of NETs, responsible
for a reduction in bacterial counts in vitro already after 30 minutes
[25]. Such a role in a short time span was not found for MRP8/
14: incubation of Klebsiella with NETs for one hour resulted in
Figure 8. MRP8/14 reduces bacterial growth of K. pneumoniae through metal chelation. Growth of K. pneumoniae was assessed for a
maximum of 24 hours in the presence of recombinant MRP8/14, MRP8 homodimer or MRP14 homodimer (50 mg/ml) (A). Bacterial growth was dose
dependently inhibited by MRP8/14 (B); the growth inhibiting effect of MRP8/14 (10 mg/ml) was reversed by the addition of zinc (C). Data are means6
SEs of at least 3 replicates and representative of triplicate experiments.
doi:10.1371/journal.ppat.1002987.g008
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reduced outgrowth as well, but this was not influenced by
coincubation with anti-MRP14 (data not shown). A previous
investigation established that MRP14 is not required for NET
formation by neutrophils [24]. We here show that MRP8/14 is an
important player in growth inhibition in late stage infection of
mouse NETs and that NETs void of MRP8/14 are unable to
inhibit the growth of K. pneumoniae. NETs in the Klebsiella-infected
lungs, which have been documented in a previous study [40],
might contribute to decreased dissemination into spleen and liver
in an MRP8/14-dependent manner via this growth inhibitory
effect. In accordance, human NETs strongly inhibited Klebsiella
growth, which was almost completely reversed by anti-MRP14
antibodies blocking the chelating effect of MRP8/14 or by the
addition of zinc. Our current data are the first to indicate that the
capacity of NETs to kill a bacterium is highly dependent on
MRP8/14 and that MRP8/14 exerts its antimicrobial effects in
NETs on Klebsiella through metal chelation. A similar MRP8/14
dependent mechanism was recently shown for killing by NETs of
the fungi Candida albicans [24] and Aspergillus nidulans [27].
In conclusion, we here document that MRP14 deficiency leads
to increased bacterial growth and dissemination accompanied by
enhanced organ damage and mortality in K. pneumoniae sepsis
originating from the lungs. MRP8/14 exerts its essential protective
role by its involvement in macrophage phagocytosis and by
directly inhibiting the growth of K. pneumoniae through divalent
cation chelation. This study shows for the first time that MRP8/14
within NETs is critical in both a murine and human system
controlling bacterial infection.
Materials and Methods
Ethics statement
Experiments were carried out in accordance with the Dutch
Experiment on Animals Act and approved by the Animal Care
and Use Committee of the University of Amsterdam (Permit
number: DIX100121, DIX101223) or carried out according to the
recommendations in the guide for the care and use of laboratory
animals conformed to Swedish animal protection laws and
applicable guidelines (djurskyddsmyndigheten DFS 2004:4) and
approved by the local Ethical Committee (Dnr A 29-09).
Mice
C57Bl/6 Wild type (Wt) mice were purchased from Charles
River Laboratories Inc. (Maastricht, the Netherlands). Mrp142/2
mice, backcrossed .10 times to a C57BL/6 background were
generated as described [28] and bred in the animal facility of the
Academic Medical Center (Amsterdam, the Netherlands). The
Animal Care and Use Committee of the University of Amsterdam
approved all experiments.
Design
Mice were intranasally inoculated with 104 K. pneumoniae
serotype 2 (ATCC 43816 Rockville, MD) in a 50 ml saline solution
(n = 7–8 per strain) and sacrificed 6, 24 or 48 hours thereafter
[36,37]. In an additional study, mice were intravenously injected
with K. pneumoniae (26103 colony forming units (cfu)) in the tail vein
and sacrificed 48 hours after infection. Collection and handling of
samples were done as previously described [36,37]. In brief, blood
was drawn into heparinized tubes and organs were removed
aseptically and homogenised in 4 volumes of sterile isotonic saline
using a tissue homogenizer (Biospec Products, Bartlesville, UK).
To determine bacterial loads, ten-fold dilutions were plated on
blood agar (BA) plates and incubated at 37uC for 16 h. In survival
studies mice (n = 12 to 16 per strain) were intranasally inoculated
with 103 or 104 K. pneumoniae and monitored for up to 10 days after
infection. Bronchoalveolar lavage (BAL) fluid was obtained from a
separate group of infected Wt mice (n = 6) at indicated time points.
The trachea was exposed through a midline incision and
cannulated with a sterile 22-gauge Abbocath-T catheter (Abbott
Laboratories, Sligo, Ireland). Bilateral BAL was performed by
instilling two 0.5 ml aliquots of sterile phosphate buffered saline
(PBS) as described earlier [36]. 0.9–1 ml of BAL fluid was
retrieved per mouse.
Assays
Lung homogenates were prepared for immune-assays as
described before [36,37]. MRP8/14 levels were measured by
ELISA [15]. Lung cytokines and chemokines TNF-a, interleukin
(IL)-1-b, IL-6, IL-10, Keratinocyte-derived chemokine (KC) and
macrophage inflammatory protein 2 (MIP-2)(all R&D systems,
Figure 9. Growth inhibition of Klebsiella by mouse and human NETs is MRP8/14 dependent. 36105 mouse neutrophils isolated from Wt
and mrp142/2 mice were induced to make neutrophil extracellular traps (NETs) and subsequently infected with 5000 cfu K. pneumoniae. Cfu counts
were determined after incubation of 7 hours at 37uC (A). 56105 human neutrophils were induced to make NETs and pretreated with a rabbit
polyclonal anti-MRP14 antibody (a-MRP14), an unspecific rabbit polyclonal control antibody (control IgG) or an excess of zinc and then infected with
100 cfu Klebsiella. Cfu counts were determined after incubation of 10 hours (B). Percentage bacterial growth in the presence of NETs was calculated
based on bacterial counts relative to medium controls without NETs. Data are expressed as box-and-whisker diagrams depicting the smallest
observation, lower quartile, median, upper quartile and largest observation of at least 5 replicates. *p,0.05 versus controls.
doi:10.1371/journal.ppat.1002987.g009
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Minneapolis, MN) and Myeloperoxidase (MPO; Hycult Biotech-
nology BV, Uden, the Netherlands) were measured using specific
ELISAs according to manufacturer’s recommendations. Plasma
TNF-a, IL-6 and IL-1b were measured by cytometric bead array
flex set assay (BD Biosciences, San Jose, CA) in accordance to the
manufacturer’s instructions. Lactate dehydrogenase (LDH), aspar-
tate aminotransferase (AST) and alanine transaminase (ALT) were
measured in plasma with kits from Sigma (St. Louis, MO), using a
Hittachi analyzer (Boehringer Mannheim, Mannheim, Germany).
Histology
Lung and liver pathology scores were determined as described
before [36–38]. In brief, lungs and livers were harvested at the
indicated time points, fixed in 10% buffered formalin, and
embedded in paraffin. 4 mm sections were stained with haema-
toxylin and eosin (HE) and analyzed by a pathologist blinded for
groups as described earlier. To score lung inflammation and
damage, the entire lung surface was analyzed with respect to the
following parameters: bronchitis, edema, interstitial inflamma-
tion, intra-alveolar inflammation, pleuritis, endothelialitis and
percentage of the lung surface demonstrating confluent inflam-
matory infiltrate. Each parameter was graded 0–4, with 0 being
‘absent’ and 4 being ‘severe’. Livers were scored according to the
following parameters: number of thrombi, number of (micro)ab-
scesses, presence and degree of inflammation, and presence and
degree of necrosis. Each parameter was graded 0–3, with 0 being
absent and 3 being severe. The total pathology score for lungs
and livers was expressed as the sum of the score for all
parameters. Granulocyte staining was done using FITC-labeled
rat anti-mouse Ly-6 mAb (Pharmingen, San Diego, CA) as
described earlier [51]. Ly-6G expression in the lung tissue
sections was quantified by digital image analysis [52]. In short,
lung sections were scanned using the Olympus Slide system
(Olympus, Tokyo, Japan) and TIF images, spanning the full tissue
section were generated. In these images Ly-6G positivity and total
surface area were measured using Image J (U.S. National
Institutes of Health, Bethesda, MD, http://rsb.info.nih.gov/ij);
the amount of Ly-6G positivity was expressed as a percentage of
the total surface area. MRP8 and MRP14 staining of lung tissue
were performed as described previously [28]. For immunostain-
ings, specimens were processed similarly as described previously
[24]. Briefly, samples were deparaffinized, rehydrated in
decreasing concentrations of EtOH, and subjected to antigen
retrieval by cooking in 10 mM citrate buffer, pH 6.0, for 10 min.
Specimens were blocked with 2% BSA and mouse Ig blocking
reagent according to manufacturer’s protocol (Vector Laborato-
ries, Burlingame, USA) in PBS/0.1% Triton for 1 h at room
temperature. Subsequently, specimens were incubated with
primary antibodies directed against myeloperoxidase (MPO)
(A0398, Dako) and histone H1 (clone AE-4, Acris) diluted in
blocking solution over night at 4uC. Primary antibodies were
detected with Alexa Fluor 488- and 568-conjugated secondary
antibodies (Life Technologies) diluted in 2% BSA in PBS/0.1%
Triton. DNA was visualized with DAPI (Life Technologies) and
slides were mounted with fluorescence mounting medium (Dako).
Pictures were taken with a Nikon C1 confocal microscope and
presented as maximum intensity projections from parts of Z-
stacks.
Whole blood stimulation
Growth-arrested bacteria were prepared as described [53] In
brief, K. pneumoniae were cultured and washed with pyrogen-free
sterile saline and resuspended in sterile PBS to a concentration of
26109 bacteria/ml. The concentrated K. pneumoniae preparation
was treated for 1 h at 37uC with 50 mg/ml Mitomycin C (Sigma-
Aldrich; Zwijndrecht, the Netherlands) to prepare alive but
growth-arrested bacteria. Subsequently, the growth-arrested K.
pneumoniae preparation was washed twice in ice-cold sterile PBS by
centrifugation at 4uC, and the final pellet was dispersed in ice-cold
PBS in the initial volume and transferred to sterile tubes.
Undiluted samples of these preparations failed to generate any
bacterial colonies when plated on BA plates, indicating successful
growth arrest. Bacteria were washed and resuspended in RPMI
and diluted to ten-fold lower bacterial concentrations (26104–
7 cfu/ml). 100 ml of heparinized whole blood obtained from 4
individual Wt, mrp142/2 and tlr42/2 [54] mice were then
incubated with 100 ml of the different bacterial concentrations in
a 96 wells plate and incubated for 6 hours at 37uC, 5% CO2.
After incubation, plates were centrifuged at 4uC and supernatant
was harvested for determination of TNF-a.
Phagocytosis assay
Phagocytosis of K. pneumoniae was determined as described
before [55]. In brief, growth-arrested bacteria were prepared as
described above and labeled with carboxyfluorescein succinimidyl
ester (CFSE, Invitrogen, Breda, the Netherlands). 50 ml heparin-
ized whole blood was incubated with 50 ml bacteria in IMDM
(Gibco) (end concentration of 16107 CFU/ml) at 37uC (n = 6 per
group) or 4uC (n = 3 per group). After 20 minutes, samples were
put on ice to stop phagocytosis. Afterwards, red blood cells were
lysed using isotonic NH4Cl solution (155 mM NH4Cl, 10 mM
KHCO3, 100 mM EDTA, pH 7.4). Neutrophils were labeled
using anti-Gr-1-PE (BD Pharmingen, San Diego, CA) and washed
twice in FACS-buffer (0.5% BSA, 0.01% NaN3, 0.35 mM EDTA
in PBS) for analysis. Peritoneal macrophages (derived from 3 mice)
were pooled, washed twice and resuspended in IMDM containing
2 mM L-glutamine and 10% fetal calf serum (FCS) (Gibco).
16105 cells per well were seeded in a 96-well flat-bottom plate in
250 mL to adhere overnight at 37uC, 5% CO2. The following day,
macrophages were washed twice with pre-warmed medium to
wash away non-adherent cells. Growth-arrested bacteria were
opsonised in 10% normal mouse serum before added to cells at a
multiplicity of infection of 100 in a volume of 100 mL. Bacteria
and macrophages were spun at 1000 RPM for 5 minutes and
incubated at 37uC (n = 8 wells per strain) or 4uC (n = 4 wells per
strain). After 1 hour, samples were washed twice with ice-cold
PBS, then thoroughly scraped from the bottom and washed again
in FACS-buffer. The degree of phagocytosis was determined using
FACSCalibur (Becton Dickinson Immunocytometry, San Jose,
CA.) The phagocytosis index of each sample was calculated as
follows: geo mean fluorescense6% positive cells.
Growth inhibition by MRPs
Recombinant mouse MRP8 and MRP14 homodimers as well
as MRP8/14 heterodimers were generated as previously
described [56]. To test growth inhibitory effects of MRPs on K.
pneumoniae, bacteria were grown to log phase and diluted to
approximately 10.000 cfu/ml in HEPES buffered RPMI. 100 ml
of this bacterial suspension was added to 100 ml of recombinant
murine MRP8 or 14 homodimer or MRP8/14 heterodimer in
HBSS (end concentration 50 mg/ml unless indicated otherwise;
n = 4–6) without Ca2+ and Mg2+ (Gibco). Bacteria and MRPs
were incubated for 0, 2, 4, 8 or 24 hours at 37uC. To test
reversibility of growth inhibitory effects on K. pneumoniae,
increasing concentrations of ZnSO4 were added to a 10 mg/ml
MRP8/14 solution. Growth was assessed by plating out ten-fold
dilutions of bacterial concentrations on BA plates and incubation
at 37uC for 16 h.
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Growth inhibition by murine NETs
Murine neutrophils were isolated from Wt and mrp142/2 mice;
animals used for these experiments were bred in the animal facility
of the Umea˚ University (Umea˚, Sweden). Experiments were
carried out according to the recommendations in the guide for the
care and use of laboratory animals conformed to Swedish animal
protection laws and applicable guidelines (djurskyddsmyndigheten
DFS 2004:4) and were approved by the local ethics committee
(Dnr A 29-09). Mature murine neutrophils were isolated from
bone marrow as previously described [57]. Briefly, bone marrow
cells from tibia and femur were singularized by using a 70-mm cell
strainer and separated by centrifugation for 30 minutes at 1500 g
on a discontinuous Percoll gradient with 52% (vol/vol), 69% (vol/
vol), and 78% (vol/vol). Neutrophils harvested from the distinct
layer between 69% and 78% were resuspended in HBSS without
Ca2+ and Mg2+ until use. Murine NETs were induced as described
earlier [24,27,57]. In a 24-well plate, 56105 Wt or mrp142/2
mouse neutrophils in 500 mL RPMI with 1% (vol/vol) mouse
serum were stimulated with 100 nM phorbol 12-myristate 13-
acetate (PMA, Sigma Aldrich, St. Louis, MO) for 20 hours at
37uC, 5% CO2 to induce NET formation. The supernatant was
discarded; NETs were washed once with RPMI and incubated
with 500 mL RPMI containing approximately 5000 cfu K.
pneumoniae. Subsequently plates were centrifuged for 5 minutes at
300 g and incubated for 7 hours at 37uC.
Growth inhibition by human NETs
Human neutrophils were isolated from peripheral blood of
healthy donors using Polymorphprep (Axis-Shield, Oslo, Norway)
according to the manufacturer’s instructions. Neutrophils were
harvested and washed with HBSS without Ca2+ and Mg2+.
Remaining red blood cells were lysed using sterile isotonic NH4Cl
solution without EDTA for 10 minutes. After lysis of red blood
cells, neutrophils were washed and resuspended in HBSS without
Ca2+ and Mg2+ until use. In a 96-well plate, 36105 human
neutrophils resuspended in 50 mL HEPES buffered RPMI (Gibco)
were stimulated with 100 nM PMA for 4 hours at 37uC, 5% CO2
to induce NET formation [25]. Sytox Green (Molecular Probes,
Carlsbad, CA) confirmed the presence of NETs (data not shown).
The supernatant was discarded and approximately 100 cfu log
phase grown K. pneumoniae, P. aeruginosa or S. aureus, resuspended in
200 mL HEPES buffered RPMI were added to the wells and spun
down for 5 minutes at 300 g. To test growth inhibiting properties
of endogenous MRP8/14 in human NETs, samples were pre-
incubated for 30 minutes with 15 mg/ml rabbit polyclonal anti-
MRP14 antibody (H00006280-D01P; Abnova, Taipei, Taiwan),
unspecific rabbit polyclonal control antibody or an excess of
ZnSO4 (1 mM), before the addition of bacteria. Overnight
bacterial growth was assessed by plating out ten-fold dilutions of
bacterial concentrations on BA plates and incubation at 37uC for
16 hours. Bacterial growth of Klebsiella is expressed as percentage
of control values (K. pneumoniae growth in media without
neutrophils with or without anti-MRP14, control antibody or
ZnSO4).
Statistical analysis
Data are expressed as box-and-whisker diagrams depicting the
smallest observation, lower quartile, median, upper quartile and
largest observation unless indicated otherwise. Differences be-
tween mrp142/2 and Wt mice were analyzed by Mann-Whitney U
test. Survival was compared by Kaplan-Meier analysis followed by
a log rank test. Analyses were done using GraphPad Prism version
5.0, Graphpad Software (San Diego, CA). Values of p,0.05 were
considered statistically significant different.
Supporting Information
Figure S1 Mrp142/2 mice show enhanced bacterial
dissemination after intravenous K. pneumoniae infec-
tion. Bacterial loads in blood (A), lung (B), spleen (C) and liver (D)
of K. pneumoniae in Wt (grey) and mrp142/2 mice (white) 48 hours
after infection. Data are expressed as box-and-whisker diagrams
depicting the smallest observation, lower quartile, median, upper
quartile and largest observation (8 mice per group). **p,0.01,
***p,0.001 versus Wt mice
(TIF)
Figure S2 MRP14 deficiency does not reduce cytokine
response in whole blood to Klebsiella infection. TNF-a
levels after a 6 hour stimulation of whole blood obtained from
individual Wt, mrp142/2 and tlr42/2 mice (n = 4 per group) with
log increasing concentrations of growth-arrested K. pneumoniae.
(TIF)
Figure S3 Decondensed nuclei of neutrophils in lungs of
Wt and mrp142/2 mice are indicators for the release of
NETs. Representative confocal immunofluorescence images of
lung sections of Wt (A–D) and mrp142/2 mice (E–H) 24 hours
after K. pneumoniae infection stained with DAPI (blue) and primary
antibodies against MPO (red) and histone H1 (green). In both Wt
and mrp142/2 lungs we found similar amounts of decondensed
nuclei from neutrophils (arrows), a prior stage of NET formation.
Scale bars indicate 10 mm.
(TIF)
Figure S4 Bacterial growth inhibition by human NETs
is MRP8/14 dependent. 56105 human neutrophils were
induced to make NETs and pretreated with a rabbit polyclonal
anti-MRP14 antibody (a-MRP14) or an unspecific rabbit
polyclonal control antibody (control IgG) and then infected with
100 cfu Staphylococcus aureus (A) or Pseudomonas aeruginosa (B). Cfu
counts were determined after incubation of 15 hours (B). Data are
expressed as box-and-whisker diagrams depicting the smallest
observation, lower quartile, median, upper quartile and largest
observation of at least 5 replicates. *p,0.05 versus controls.
(TIF)
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